Cardiol Therapeutics Inc. (CRDL.TO)
Chart Events
Performance Outlook
| Previous Close | 1.2500 |
| Open | 1.2900 |
| Bid | 1.2500 x 0 |
| Ask | 1.2600 x 0 |
| Day's Range | 1.2500 - 1.2900 |
| 52 Week Range | 0.6100 - 1.6400 |
| Volume | |
| Avg. Volume | 85,496 |
| Market Cap | 80.784M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.05 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRDL.TO
Related Research
NewsfileCardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 PatientsToronto, Ontario--(Newsfile Corp. - September 19, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapie
NewsfileCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview which will be broadcast live at the Canaccord Genuity 43rd Annual Growth Conference, at
NewsfileCardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice on August 7, 2023 from The Nasdaq Stock Market LLC ("Nasdaq") stating the Company has regained compliance with the minimum bid price requirement unde
